06:57 AM EDT, 07/09/2025 (MT Newswires) -- Exact Sciences ( EXAS ) said Wednesday that its Oncodetect molecular residual disease test has received Medicare coverage for serial use in patients with stage 2, 3 and resectable stage 4 colorectal cancer in the adjuvant and recurrence monitoring settings over a five-year period.

The Oncodetect test is now covered by Medicare through the Centers for Medicare & Medicaid Services' Molecular Diagnostic Services Program, the company said.

The Oncodetect test is designed to provide a more personalized approach to detecting and monitoring residual cancer in patients with solid tumors.

Shares of the company were up 2.6% in recent premarket activity.